Introduction and objectivesThe outbreak of COVID-19 epidemic imposed temporary changes in the management of patients with chronic diseases MESHD. We analyzed the impact of COVID-19 epidemic in patients with Systemic Sclerosis MESHD (SSc) receiving intravenous iloprost infusions for digital ulcers HP ulcers MESHD (DU) treatment.MethodsDuring the epidemic, iloprost infusion therapy in our Hospital was guaranteed; patients were regularly contacted by telephone before the scheduled infusions. DU were evaluated with DUCAS (DU Clinical Assessment Score).ResultsBetween 20th February and 31st May 2020, 47/64 SSc patients did not receive at least one of the scheduled infusions, for patients fear and/or logistical difficulties (43 cases), COVID-19 (2), or other intercurrent diseases MESHD (2). At the last evaluation before 20th February DUCAS was not different between patients who stopped the therapy and those who continued it. The 2 groups had similar rate of new DU during the emergency MESHD period, but DUCAS slightly increased during therapy discontinuation, decreasing after resuming it. After COVID-19, one patient underwent a fingertip sub-amputation, and an 85-year-old male TRANS with multiple comorbidities died for complications related to the infection MESHD.ConclusionsMost SSc patients briefly discontinued iloprost therapy, without increase of new DU number, but with a slight increase of their severity. The regular telephonic contact helped the management that, although not optimal, was adapted to the needs of the individual patient during this emergency MESHD period. DUCAS proved to be a useful tool for rheumatologists. COVID-19 had serious consequences in the two patients who contracted it.